文献速递前列腺癌

3.0-T磁共振引导经直肠靶向前列腺穿刺在重复活检人群中的诊断表现、并发症与学习曲线

In-bore 3.0-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy in a Repeat Biopsy Population: Diagnostic Performance, Complications, and Learning Curve.
PubMed 文献 · Urology · 2018-01-09

该研究评估了2014-2017年近4年学习曲线下,3.0-T磁共振引导经直肠靶向前列腺穿刺(MRGB)在重复活检人群中的诊断表现和并发症率。142例既往活检阴性但PSA升高、PI-RADS 3-5病灶的男性接受MRGB,前列腺癌检出率57%,有临床意义前列腺癌(csPCa)在PI-RADS 3、4、5病灶中分别为9%、25%、48%,需医疗干预的并发症6%。

要点

  • 重复活检人群中MRGB总前列腺癌检出率为57%。
  • PI-RADS 3、4、5病灶的前列腺癌检出率分别为46%、52%、74%。
  • PI-RADS评分、年龄、既往活检次数和PSA密度是csPCa的显著预测因素。

核心结论

  • 在重复活检背景下,MRGB对PI-RADS 3-5病灶检测csPCa具有足够的诊断性能,且并发症率低。
  • 穿刺操作技能可快速掌握,索引病灶位置不影响癌检出率。

研究设计与样本

  • 回顾性评估2014-2017年近4年学习曲线下,142例既往活检且因PSA高持续怀疑前列腺癌、PI-RADS 3-5病灶的连续男性接受MRGB。

主要发现

  • 前列腺癌见于57%的患者。
  • PI-RADS 3、4、5病灶的癌检出率分别为46%、52%、74%。
  • csPCa分别见于9%、25%、48%的患者。
  • 单因素分析中PI-RADS评分(P = .0067)是csPCa的显著预测因素。
  • 多因素logistic回归中年龄(P = .0007)、既往活检次数(P = .0236)和PSA密度(P = .0250)是csPCa的显著预测因素。

关键数值与推荐

  • 索引病灶位置和大小、获取穿刺条数和长度、操作者经验不影响癌检出率。
  • 学习曲线方面,穿刺时间和获取穿刺条数在10例操作后显著改善。
  • 需要医疗干预的并发症见于6%(感染2%)。

临床怎么用

  • 对既往活检阴性但持续怀疑前列腺癌且PI-RADS 3-5病灶的患者,可考虑MRGB进行靶向穿刺。
  • 结合PI-RADS评分、年龄、既往活检次数和PSA密度综合预测csPCa风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the diagnostic performance and complication rate of the in-bore magnetic resonance imaging-guided transrectal targeted prostate biopsy (MRGB) in a repeat biopsy population on the basis of a nearly 4-year learning curve (2014-2017). MATERIALS AND METHODS: A total of 142 consecutive males with previous biopsies and persistent suspicion of prostate cancer (PCa) due to high prostate-specific antigen level initially underwent MRGB in the case of prostate imaging reporting and data system (PI-RADS) 3-5 lesions. Cancer detection rate (CDR), number and length of cores, biopsy time, operator experience, complications, and prediction of clinically significant (cs) PCa (Gleason score ≥7) were investigated. RESULTS: PCa was found in 57% of patients. CDR in PI-RADS 3, 4, and 5 lesions were 46%, 52%, and 74%, respectively. csPCa was found in 9%, 25%, and 48% of patients. In univariate analysis the PI-RADS score (P = .0067) was a significant predictor of csPCa. In the multivariate logistic regression, age (P = .0007), number of previous biopsies (P = .0236), and prostate-specific antigen density (P = .0250) were significant predictors of csPCa. Location and size of the index lesion, number and length of cores obtained, and operator experience did not affect CDR. Concerning learning curve, biopsy time and number of cores obtained improved significantly after 10 procedures. Complications requiring medical intervention were seen in 6% (infections 2%). CONCLUSION: In a re-biopsy setting the MRGB showed sufficient diagnostic performance in detecting csPCa in PI-RADS 3-5 lesions, with low complication rate. The skill of performing biopsy is quickly acquired, and location of index lesion did not have an impact on CDR.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Friedl A, Schneeweiss J, Sevcenco S, et al. In-bore 3.0-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy in a Repeat Biopsy Population: Diagnostic Performance, Complications, and Learning Curve. Urology. 2018. PMID: 29330001. doi:10.1016/j.urology.2017.12.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。